Enter your e-mail address below
to reset your password.
Please activate your registration
by clicking the link in the activation email
or click submit to resend the activation email.
Please check your spam folder too...
Check your mailbox to activate your registration.
Please check your spam folder too.
Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the acquisition of Glenmark’s CNS product portfolio in Poland.
Following the transaction, the Glenmark CNS commercial team in Poland will join Neuraxpharm Polska’s existing sales and marketing organization to create a strong player in the Polish CNS market, Neuraxpharm said in a press release.
Glenmark’s established portfolio of 20 proprietary CNS products in Poland comprise both prescription medicines and Consumer Healthcare products. The terms of the transaction were not disclosed.